GlobeNewswire Inc.··Mink TherapeuticsMiNK Therapeutics Advances iNKT Cell Therapy for Hard-to-Treat Gastric Cancer
MiNK Therapeutics will present Phase II data on agenT-797 combined immunotherapy for PD-1 refractory gastroesophageal cancer at AACR 2026.
INKTimmunotherapyPhase II trial